Skip to content

Trial of Long-term Therapeutic Hypothermia for Poor-grade Aneurysmal Subarachnoid Hemorrhage

A Multi-center, Randomized, Controlled Trial to Investigate the Efficacy and Safety of Long-term Therapeutic Hypothermia in Adult Patients With Poor-grade Aneurysmal Subarachnoid Hemorrhage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03442608
Enrollment
200
Registered
2018-02-22
Start date
2018-03-01
Completion date
2020-12-31
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Subarachnoid Hemorrhage, Hypothermia

Brief summary

This study is a prospective, multi-centre, randomized,controlled trial to compare the efficacy of long-term mild hypothermia with normothermic intensive management in patients with poor-grade aneurysmal subarachnoid hemorrhage. The primary hypothesis is that the induction of mild hypothermia (maintained at 32-35℃) for at least 5 days would improve the outcome of patients at six months post hemorrhage compared with normothermia.

Detailed description

Aneurysmal subarachnoid hemorrhage (aSAH), especially poor-grade aSAH, is a medical emergency with very high morbidity and mortality rates. SAH constitutes a major public health concern in developed and developing countries. There were several clinical trials of hypothermia for aSAH conducted, however, with conflicting results. Hypothermia therapy treatment is currently used in our department and other large neurosurgical centers across China to decrease the intracranial pressure (ICP), mitigate some of the destructive processes, and improve the functional outcome of patients with poor-grade aSAH. When the decision was made, the patients would be placed in wrapped cooling blankets or intravascular cooling device after they were sedated, intubated and mechanically ventilated. The patients would receive continuous infusions of some drugs using an infusion pump to prevent shivering. Once the patient's rectal, nasopharyngeal or blood temperature reached 32˚C, it was kept at approximately that temperature (32-35˚C) 3 to 7 days. Then the patients were passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.25˚C/hour, by gradual adjustment of the blanket thermostat. The present multi-center, randomized controlled trials is designed to investigate the efficacy and safety of long-term (3 days) mild hypothermia versus normothermia on the outcome of patients with poor-grade aSAH. The primary outcome is the neurological function assessed at 1,3, 6 months post injury with the Glasgow Outcome Score (GOS). Additionally, the following data will also be recorded and compared: the baseline data, Glasgow Coma Score,imaging examination (e.g. CT scan), intracranial pressure, laboratory tests (e.g. blood routine test, liver and kidney function, blood gas analysis, etc), the complications (e.g. pneumonia, significant bleeding) and so on.

Interventions

PROCEDUREZoll 2000 and/or CureWrap 3500 cooling system

Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.

Sponsors

First Affiliated Hospital of Fujian Medical University
CollaboratorOTHER
Central South University
CollaboratorOTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
CollaboratorOTHER
Tang-Du Hospital
CollaboratorOTHER
First Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
The First Hospital of Jilin University
CollaboratorOTHER
The First Affiliated Hospital of Dalian Medical University
CollaboratorOTHER
Shanxi Cardiovascular Hospital
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
First Affiliated Hospital of Wenzhou Medical University
CollaboratorOTHER
Shandong Provincial Hospital
CollaboratorOTHER_GOV
Yantai Yuhuangding Hospital
CollaboratorOTHER
Beijing Tiantan Hospital
CollaboratorOTHER
Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 - 65 years within 72 hours after subarachnoid hemorrhage; * Neurosurgical clipping or coiling for aneurysm; * Hunt-Hess IV-V scale; * The intracranial pressure is more than 20 mmHg.

Exclusion criteria

* GCS of 3 with bilateral fixed and dilated pupils; * No spontaneous breathing or cardiac arrest at the scene of hemorrhage; * No consent; * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Neurological function6 months after hemorrhageThe neurological function will be evaluated at 6 months after hemorrhage by 2 specialized investigators who are unaware of the patients' allocation according to five-category Glasgow Outcome Scale as follows: 1, death; 2, vegetative state - unable to interact with the environment; 3, severe disability - unable to live independently but able to follow commands; 4, moderate disability - capable of living independently but unable to return to work or school; and 5, good recovery - able to return to work or school.

Secondary

MeasureTime frameDescription
Intracranial pressureAdmission, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 14, until the monitor is removedThe effect of long-term hypothermia on ICP control will be determined.
Length of ICU stay6 months post hemorrhageThe numbers of days in the ICU
Length of hospital stay6 months post hemorrhageThe numbers of days in the hospital.
Frequency of complications6 months post hemorrhageFrequency of complications during the the study such as pneumonia, coagulation disturbance,electrolyte disturbances, liver and kidney function abnormality will be recorded and compared between groups.
Mortality rate6 months after hemorrhageThe proportion of death will be determined

Contacts

Primary ContactXin Qu, MD,PhD
xinqu0213@126.com86-10-83198633

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026